Antitumor effects of interferon-ω: In vivo therapy of human tumor xenografts in nude mice

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4064-4068

  Horton, Holly M ^a   Hernandez, Pepe ^a   Parker, Suezanne E ^a   Barnhart, Kerry M ^a  

^a VICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; OMEGA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; MELANOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; FEMALE; HUMANS; INTERFERON TYPE I; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SKIN NEOPLASMS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033566988     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Leaman, D. W. Mechanism of interferon action. Prog. Mol. Subcell. Biol., 20: 101-142, 1998.
2. Capon, D. J., Shepard, H. M., and Goeddel, D. V. Two distinct families of human and bovine interferon-α genes are coordinately expressed and encode functional polypeptides. Mol. Cell. Biol., 5: 768-779, 1985.
3. Feinstein, S. I., Mory, Y., Chernajovsky, Y., Maroteaux, L., Nir, U., Lavie, V., and Revel, M. Family of human α-interferon-like sequences. Mol. Cell. Biol., 5: 510-517, 1985.
4. Hauptmann, R., and Swetly, P. A novel class of human type I interferons. Nucleic Acids Res., 13: 4739-4749, 1985.
5. Flores, I., Mariano, T. M., and Pestka, S. Human interferon omega (ω) binds to the α/B receptor. J. Biol. Chem., 266: 19875-19877, 1991.
6. Adolf, G. R. Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte interferon. Virology, 175: 410-417, 1990.
7. Adolf, G. R., Maurer-Fogy, I., Kalsner, I., and Cantell, K. Purification and characterization of natural human interferon ω1: two alternative cleavage sites for the signal peptidase. J. Biol. Chem., 265: 9290-9295, 1990.
8. II 1): comparison with other human interferons. J. Gen. Virol., 68: 1669-1676, 1987.
9. Cutrone, E. C., and Langer, J. A. Contributions of cloned type I interferon receptor subunits to differential ligand binding. FEBS Lett., 404: 197-202, 1997.
10. th anniversary of the discovery of interferons. Cancer Res., 58: 2489-2499, 1998.
11. Brosjo, O., Bauer, H. C. F., Brostrom, L-A., Nilsson, O. S., Reinholt, F. P., and Tribukait, B. Growth inhibition of human osteosarcomas in nude mice by human interferon-α: significance of dose and tumor differentiation. Cancer Res., 47: 258-262, 1987.
12. Ozzello, L., Habif, D. V., De Rosa, C. M., and Cantell, K. Effects of intralesional injections of interferons-α on xenografts of human mammary carcinoma cells (BT 20 and MCF-7). J. Interferon Res., 8: 207-215, 1988.
13. Baisch, H., Otto, U., and Kloppel, G. Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor α and/or α interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies. Cancer Res., 50: 6389-6395, 1990.
14. Van Moorselaar, R. J. A., van Stratum, P., Borm, G., Debruyne, F. M., and Schalken, J. A. Differential antiproliferative activities of α- and γ-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate, 18: 331-344, 1991.
15. Ohnuma, T., Szrajer, L, Holland, J. F., Kurimoto, M., and Minowada, J. Effects of natural interferon α, natural tumor necrosis factor α and their combination on human mesothelioma xenografts in nude mice. Cancer Immunol. Immunother., 36: 31-36, 1993.
16. Zhang, J-F., Hu, C., Geng, Y., Selm, J., Klein, S. B., Orazi, A., and Taylor, M. W. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl. Acad. Sci. USA, 93: 4513-4518, 1996.
17. Iqbal Ahmed, C. M., Sugarman, B. J., Johnson, D. E., Bookstein, R. E., Saha, D. P., Nagabhushan, T. L., and Wills, K. N. In vivo tumor suppression by adenovirus-mediated interferon α2b gene delivery. Hum. Gene Ther., 10: 77-84, 1999.
18. Weiss, K. Safety profile of interferon-α therapy. Semin. Oncol., 25: 9-13, 1998.
19. Ozer, H., Wiernik, P. H., Giles, F., and Tendler, C. Recombinant interferon-α therapy in patients with follicular lymphoma. Cancer (Phila.), 82: 1821-1830, 1998.
20. Nieroda, C., Pestka, S., Schlom, J., and Greiner, J. W. Interferon-ω augments major histocompatibility and human tumor-associated antigen expression. Mol. Cell. Differ., 4: 335-351, 1996.
21. Tiefenthaler, M., Geisen, F., Schirmer, M., and Konwalinka, G. A comparison of the antiproliferative properties of recombinant human IFN-α2 and IFN-ω in human bone marrow culture. J. Interferon Cytokine Res., 17: 327-329, 1997.
22. Roberts, R. M., Liu, L., and Alexenko, A. New and atypical families of type I interferons in mammals: comparative functions, structures, and evolutionary relationships. Prog. Nucleic Acid Res., 56: 287-325, 1997.
23. Hartikka, J., Sawdey, M., Comefert-Jensen, F., Margalith, M., Barnhart, K., Nolasco, M., Vahlsing, H. L., Meek, J., Marquet, M., Hobart, P., Norman, J., and Manthorpe, M. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther., 7: 1205-1217, 1996.
24. Horn, N., Meek, J., Budahazi, G., and Marquet, M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum. Gene Ther., 6: 565-573, 1995.
25. Felgner, J. H., Kumar, R., Sridhar, C. N., Wheeler, C. J., Tsai, Y. J., Border, R., Ramsey, P., Martin, M., and Felgner, P. L. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem., 269: 2550-2561, 1994.
26. Tomayko, M. M., and Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol., 24: 148-154, 1989.
27. + T-cell immunity. Cancer Gene Ther., 5: 321-330, 1998.
28. Stopeck, A. T., Hersh, E. M., Akporiaye, E. T., Harris, D. T., Grogan, T., Unger, E., Warneke, J., Schluter, S. F., and Stahl, S. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J. Clin. Oncol., 15: 341-349, 1997.
29. Horton, H. M., Anderson, D., Hernandez, P., Barnhart, K. M., Norman, J. A., and Parker, S. E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α. Proc. Natl. Acad. Sci. USA, 96: 1553-1558, 1999.